Oventus enters into first agreements with American sleep medicine groups to deliver the O2Vent® Sleep Treatment Platform to patients under the ‘lab in lab’ model
Key points:
-
Oventus signs first material agreements with sleep medicine groups in the United States for its O2Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)
-
The exclusive agreements to supply dental sleep medicine solutions are with 8 sleep facilities in Texas, Arizona and New Mexico
-
Contracts further validate demand for Oventus sleep treatment platform and ‘lab in lab’ delivery model
-
Oventus expects to secure further agreements across North America over the next 12-24 months
-
Negotiations ongoing with multiple groups across Canada, the US and Australia with a view to significant scaling through the end of calendar 2019 and 2020
For further information please download the attached PDF:
Download this document
